Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer

Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer

Background Programmed death 1 (PD-1) inhibitor demonstrated durable antitumor activity in advanced esophageal squamous cell carcinoma (ESCC), but the clinical benefit of perioperative immunotherapy in ESCC remains unclear. This study evaluated the efficacy and safety of neoadjuvant chemoradiotherapy...

Full description

Bibliographic Details
Main Authors: Qiang Liu, Qing Ye, Xin Xu, Lei Shen, Yao Zhang, Bin Hu, Haiyan Chen, Xiaojing Zhao, Zhiyong Sun, Chenpeng Zhang, Haiping Lin, Ling Rong, Xiaohang Wang, Yong-Rui Bai, Xiumei Ma
Format: Article
Language:English
Published: BMJ Publishing Group 2024-03-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/3/e008631.full

Internet

https://jitc.bmj.com/content/12/3/e008631.full

Similar Items